- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:14 | PENTIXAPHARM HOLDING AG festigt ihre Stärke | 7 | Maximilian Berger | ||
| 18:48 | Oakmark Global Concentrated Strategy adds SNY; exits MBGAF and RHHBY | 4 | Seeking Alpha | ||
| 18:42 | Lilly's Omvoh shows durable remission in Crohn's disease patients | 4 | Investing.com | ||
| 18:42 | ClearBridge International Value Strategy adds RHHBY and MKGAF; exits GRRMF, AKESF, and HKMPF | 3 | Seeking Alpha | ||
| 18:25 | Herbizid Glyphosat: Donald Trump stärkt die Bayer AG | 32 | FAZ | ||
| 18:23 | OXURION: Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC | 144 | Actusnews Wire | Leuven, BELGIUM - February 19, 2026 - 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1... ► Artikel lesen | |
| 17:54 | Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge | 3 | Seeking Alpha | ||
| 17:34 | Cosmos Health Inc.: Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value | 192 | GlobeNewswire (Europe) | CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic... ► Artikel lesen | |
| 17:30 | Orexo AB: Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs | 143 | GlobeNewswire (Europe) | The Board of Orexo AB (publ) has today decided to convert 416,417 Class C shares into ordinary shares and to subsequently convey 416,417 ordinary shares to certain participants in the long-term incentive... ► Artikel lesen | |
| 17:23 | Broker tips: Haleon, Dunelm | 3 | Sharecast | ||
| 17:18 | Corcept falls as appeals court sides with Teva in Korlym patent dispute | 8 | Seeking Alpha | ||
| 17:10 | Merck to seek 2nd-season RSV nod for Enflonsia in hot pursuit of Sanofi, AstraZeneca's Beyfortus | 3 | FiercePharma | ||
| 16:53 | Berenberg slightly lowers target price on Haleon | 3 | Sharecast | ||
| 16:46 | Herantis Pharma plc: Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096 | 173 | GlobeNewswire (Europe) | Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson's disease, following completion of study preparations
Espoo, Finland, 19 February 2026: Herantis Pharma... ► Artikel lesen | |
| 16:39 | Nextleaf expands national commercial infrastructure | 1 | The Market Herald Canada | ||
| 16:30 | GSK PLC - Director/PDMR Shareholding | 1 | RNS | ||
| 16:18 | Craft brewer Tilray inks licensing agreement for Carlsberg beer in the US | 6 | Food Dive | ||
| 16:17 | DocMorris weist Zusammenhang zwischen ePA-Kritik und Geschäft zurück | 8 | cash | ||
| 15:58 | Madrigal: Starker Rezdiffra-Umsatz kann deutliche Gewinnverfehlung nicht ausgleichen | 3 | Investing.com Deutsch | ||
| 15:58 | Zealand Pharma: Starke Finanzlage untermauert ambitionierte Strategie bei Stoffwechselerkrankungen | 7 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| BAYER | 32 | 36 | -0,51 % | Die Gelddruckmaschine Krebsforschung: Wie Bayer, Vidac Pharma und Pfizer Ihr Depot bereichern können | Die Onkologie wird 2026 zum Härtetest für die Pharmaindustrie. Nie zuvor standen derart viele hochspezialisierte Wirkstoffe gleichzeitig vor der Markteinführung. Während Checkpoint-Hemmer und zielgerichtete... ► Artikel lesen | ||
| BAUSCH HEALTH | 9 | 4 | +0,27 % | Bausch Health Companies Posts Q4 Loss | OTTAWA (dpa-AFX) - Bausch Health Companies Inc. (BHC, BHC.TO) on Wednesday reported a net loss of $112 million for the fourth quarter, compared with a consolidated net income of $93 million... ► Artikel lesen | ||
| MERCK & CO | 7 | 43 | 0,00 % | Merck & Co., Inc.: Merck Announces Positive New Data for ENFLONSIA (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons | Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S. FDA and other regulatory authorities
Merck (NYSE: MRK), known as MSD... ► Artikel lesen | ||
 | NOVO NORDISK | 7 | 40 | -1,45 % | Novo Nordisk: Turbulente Wochen - und nun? | Bei Novo Nordisk ging es in dem noch jungen neuen Jahr bislang turbulent zu. Der dänische Pharmakonzern eröffnete das Jahr mit der spektakulären Einführung der weltweit ersten GLP-1-Pille gegen Adipositas.... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 6 | 7 | -7,82 % | Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge | |||
| CASSAVA SCIENCES | 4 | 2 | -2,46 % | Cassava Sciences: Aktie legt nach Einstellung von DOJ-Ermittlungen zu | |||
| COSMOS HEALTH | 4 | 2 | +0,12 % | Cosmos Health Inc.: Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value | CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic... ► Artikel lesen | ||
| CURALEAF | 4 | 1 | 0,00 % | Allianz der Giganten? Wie Bioxyne und Curaleaf den globalen Markt für medizinisches Cannabis und Psychedelika formen | |||
| ELI LILLY | 3 | 125 | -0,13 % | Mesoblasts Durchbruchsmoment: Vom Biotech-Überlebenskünstler zum kommerziellen Wettbewerber. Wohin als Nächstes? | |||
| GSK | 3 | 64 | -2,19 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für GSK von 2100 auf 2450 Pence angehoben und die Einstufung auf "Buy" belassen. Die Aktie des Pharmakonzerns habe zuletzt kräftig... ► Artikel lesen |
- Alle
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| DOCMORRIS AG | 5,935 | 8,88 | +50 % | 4 | 5 | 3 | |||
| SCHOTT PHARMA AG & CO KGAA | 15,100 | 19,20 | +27 % | 8 | 14 | - | |||
| SANOFI SA | 78,82 | 97,62 | +24 % | 16 | 18 | - | |||
| NOVO NORDISK A/S | 41,080 | 47,68 | +16 % | 25 | 19 | 5 | ||
| ELI LILLY AND COMPANY | 864,60 | 968,78 | +12 % | 1 | - | - | |||
| MERCK KGAA | 127,90 | 140,50 | +10 % | 9 | 3 | - | |||
| PFIZER INC | 22,730 | 23,83 | +5 % | 1 | 7 | - | |||
| ROCHE HOLDING AG GS | 402,90 | 382,67 | -5 % | 12 | 22 | 5 | |||
| ASTRAZENECA PLC | 176,75 | 161,32 | -9 % | 19 | 1 | 6 | |||
| NOVARTIS AG | 138,32 | 126,22 | -9 % | 8 | 9 | 2 | |||
| DERMAPHARM HOLDING SE | 37,850 | 34 | -10 % | - | 1 | - | |||
| BAYER AG | 45,575 | 39,69 | -13 % | 23 | 17 | 1 | |||
| GSK PLC | 25,410 | 22,06 | -13 % | 3 | 14 | 9 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.